US · ADTX
Aditxt, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Mountain View, VA 23219
- Website
- aditxt.com
Price · as of 2024-12-31
$0.20
Market cap 9.84K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $586,634.22 | +300,683,764.68% |
| Intrinsic Value(DCF) | $3,545,289.53 | +1,817,165,215.22% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $19,976,295.40 | +10,239,003,177.81% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $7,480,600,064.00 | ||||
| 2021 | $847,500,032.00 | ||||
| 2022 | $48,138,000.00 | $19,255,258.29 | $0.00 | $0.00 | $0.00 |
| 2023 | $4,203,600.00 | $2,273,563.31 | $0.00 | $0.00 | $5,319,786.03 |
| 2024 | $1,469.00 | $586,634.22 | $10,350,590.96 | $0.00 | $19,976,295.39 |
AI valuation
Our deep-learning model estimates Aditxt, Inc.'s (ADTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $586,634.22
- Current price
- $0.20
- AI upside
- +300,683,764.68%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3,545,289.53
+1,817,165,215.22% upside
Graham-Dodd
—
— upside
Graham Formula
$19,976,295.40
+10,239,003,177.81% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ADTX | Aditxt, Inc. | $0.20 | 9.84K | +300,683,765% | +1,817,165,215% | — | +10,239,003,178% | 0.00 | 0.02 | 1.28 | 30.55 | -0.01 | 0.02 | -367.95% | -20796.36% | -25708.85% | -276.39% | 7.12% | -89.79% | 0.78 | -3.78 | 0.09 | 35.64 | -0.23 | 3863.00% | -7923.00% | -984.00% | -9785.19% | -0.72 | 4.28% | 0.00% | 0.00% | 8689.62% | 29.64 | 49.27 | -6164.42 | -10.97 |
| AIMD | Ainos, Inc. | $1.64 | 7.91M | +1,477% | -27% | — | +6,696% | -1.56 | 1.50 | 1120.96 | -3.32 | — | -2.82 | -153.73% | -66772.17% | -71702.26% | -74.38% | -53.08% | -49.00% | 0.77 | -22.45 | 1.10 | 0.98 | -0.86 | -5357.00% | -8302.00% | 2176.00% | -25.09% | -1.47 | -22.36% | 0.00% | 0.00% | 0.00% | -2.26 | -5.38 | 1512.06 | -3.08 |
| ANL | Adlai Nortye Ltd. | $7.86 | 245.52M | +169% | — | — | — | -0.47 | 0.97 | — | 0.19 | — | 0.97 | 0.00% | — | — | -98.90% | -2580.88% | -51.49% | 1.07 | -28.22 | 1.41 | 1.37 | 0.70 | -6829.00% | -10000.00% | -855.00% | -211.30% | -1.14 | -2444.23% | 0.00% | 0.00% | 0.00% | 0.17 | 0.17 | — | -10.34 |
| APLM | Apollomics, Inc. | $20.21 | 22.3M | +737% | +1,097% | — | +18,417% | -0.11 | 1.22 | 29.90 | 0.07 | — | 1.89 | 100.00% | -21280.81% | -27201.01% | -233.67% | -2034.57% | -157.28% | 0.20 | -235.40 | 1.39 | 1.34 | 0.21 | -7724.00% | -7588.00% | -3343.00% | -485.92% | -3.88 | -1389.04% | 0.00% | 0.00% | 0.00% | 0.07 | 0.10 | -14.54 | -84.82 |
| ATHA | Athira Pharma, Inc. | $6.75 | 26.62M | — | — | — | — | -0.14 | 0.29 | — | 0.38 | — | 0.29 | 0.00% | — | — | -110.77% | 967.28% | -88.52% | 0.03 | — | 4.18 | 3.90 | 0.49 | -1845.00% | — | -381.00% | -740.33% | -7.40 | 931.82% | 0.00% | 0.00% | 0.00% | 0.37 | 0.38 | — | -13.92 |
| BLRX | BioLineRx Ltd. | $2.83 | 12.31M | +2,367% | — | — | — | -27.55 | 18.87 | 8.78 | 63.67 | — | 84.33 | 67.99% | -70.52% | -31.86% | -69.11% | 441.68% | -17.93% | 1.12 | -2.23 | 1.76 | 1.52 | 1.18 | -8723.00% | 50292.00% | 9178.00% | -17.29% | -2.85 | 950.70% | 0.00% | 0.00% | 1.08% | -12.22 | -5.68 | 8.62 | -9.02 |
| CTXR | Citius Pharmaceuticals, I… | $0.74 | 8.27M | — | — | — | — | -0.33 | 0.19 | — | -0.28 | — | -0.38 | 0.00% | — | — | -57.75% | -58.28% | -32.10% | 0.03 | -143.87 | 0.62 | 0.09 | 0.06 | -4338.00% | — | -585.00% | -203.36% | -0.59 | -40.17% | 0.00% | 0.00% | 0.00% | -0.28 | -0.40 | — | -3.53 |
| GOVX | GeoVax Labs, Inc. | $1.60 | 1.62M | — | +969% | — | — | -0.35 | 1.76 | 2.24 | -0.14 | — | 1.78 | 97.59% | -635.83% | -631.98% | -462.31% | 4381.85% | -286.62% | 0.00 | -1176.34 | 2.55 | 1.98 | 0.22 | -5284.00% | — | -209.00% | -278.43% | -7.94 | 4303.75% | 0.00% | 0.00% | 0.00% | -0.13 | -0.14 | 0.85 | -29.47 |
| ICU | SeaStar Medical Holding C… | $2.76 | 7.7M | — | — | — | — | -0.27 | -3.10 | 50.20 | -0.23 | — | -3.10 | 100.00% | -13216.30% | -18392.59% | 309.35% | 425.16% | -607.76% | -0.26 | -73.12 | 0.55 | 0.28 | 0.05 | -7809.00% | — | 5563.00% | -236.21% | -2.34 | 381.44% | 0.00% | 0.00% | 149.78% | -0.31 | -0.35 | 40.98 | -54.76 |
| MBRX | Moleculin Biotech, Inc. | $2.39 | 2.89M | — | — | — | — | -0.18 | 0.64 | — | 0.00 | — | -0.75 | 0.00% | — | — | -135.80% | -1009.89% | -78.93% | 0.08 | — | 0.97 | 0.80 | 0.14 | -5806.00% | — | -144.00% | -619.14% | -4.45 | -905.04% | 0.00% | 0.00% | 0.00% | 0.00 | 0.00 | — | -17.68 |
| THAR | Tharimmune, Inc. | $5.12 | 202.4M | — | — | — | — | -0.16 | 1.51 | — | 0.13 | — | 1.51 | 0.00% | — | — | -233.69% | 613.15% | -166.32% | 0.00 | -908.64 | 1.54 | 1.47 | 0.29 | -9121.00% | — | 4934.00% | -553.30% | -4.52 | 537.61% | 0.00% | 0.00% | 0.00% | 0.13 | 0.15 | — | -24.00 |
About Aditxt, Inc.
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
- CEO
- Amro A. Albanna
- Employees
- 26
- Beta
- 1.51
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3,545,289.53 ÷ $0.20) − 1 = +1,817,165,215.22% (DCF, example).